Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price traded up 2% on Thursday . The company traded as high as $2.60 and last traded at $2.55. 500 shares changed hands during trading, a decline of 46% from the average session volume of 929 shares. The stock had previously closed at $2.50.
Molecular Partners Stock Performance
The company’s 50-day simple moving average is $2.43 and its 200-day simple moving average is $3.02.
About Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.
Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.
Featured Articles
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
